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Olivier Gevaert1*, Robert Tibshirani2 and Sylvia K Plevritis3Abstract
Aberrant DNA methylation is an important mechanism that contributes to oncogenesis. Yet, few algorithms exist
that exploit this vast dataset to identify hypo- and hypermethylated genes in cancer. We developed a novel computational
algorithm called MethylMix to identify differentially methylated genes that are also predictive of transcription. We apply
MethylMix to 12 individual cancer sites, and additionally combine all cancer sites in a pancancer analysis. We discover
pancancer hypo- and hypermethylated genes and identify novel methylation-driven subgroups with clinical implications.
MethylMix analysis on combined cancer sites reveals 10 pancancer clusters reflecting new similarities across malignantly
transformed tissues.Background
DNA methylation is being increasingly recognized as an
important process underlying oncogenesis [1]. Besides
genetic mutations and copy number alterations, differen-
tial methylation is an alternative mechanism that is cap-
able of altering the normal state and driving a wide
range of cancers [1-3]. Recent studies have identified
DNA methylation, including genome-wide DNA methy-
lation, in normal tissues and cancer [1,4-6]. Irizarry
et al. [5] concluded that DNA methylation is mostly lo-
cated in CpG shores and conserved between human and
mouse. Ruike et al. [4] analyzed DNA methylation in
breast cancer cell lines and showed that methylation is
altered during the epithelial to mesenchymal transition.
Hon et al. [7] showed that extensive hypomethylation is
present in intergenic regions in breast cancer and is mu-
tually exclusive with repressive histone methylation (that
is, H27K3me3 and H3K9me3). Berman et al. [6] identi-
fied focal regions of hypermethylation within long-range
regions of hypomethylation using sequencing in colorec-
tal cancer. Collectively, these studies are beginning to re-
veal a methylation map that is critical to understand
epigenetic drivers of cancer.
Many prior studies have identified hypo- or hyperme-
thylation of cancer based on heuristic measures
(reviewed in [8]). However, few studies formalize the* Correspondence: ogevaert@stanford.edu
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unless otherwise stated.identification of DNA methylation-driven genes using a
model-based approach. We propose a method called
MethylMix that aims to derive key methylation-driven
genes in cancer based on three key criteria. First, the de-
termination of the degree of methylation should not rely
on arbitrary thresholds. Second, the identification of a
cancer gene as hypo- or hyper-methylated should be
made by comparing its differential methylation state in
cancer versus normal tissue. Finally, the identification of
genes that are hypo- and hypermethylated in cancer and
likely drivers should be selected as having a significant
predictive effect on gene expression, thereby implying
that their methylation is predictive of transcription and
thus functionally relevant.
Here we present and apply MethylMix on over 4,000
tumors across 12 cancer sites from The Cancer Genome
Atlas (TCGA). MethylMix is an algorithm that produces
transcriptionally predictive and differentially methylated
genes in cancer that serve as potential epigenetic driver
genes of malignancy and, in this manner, provides a
complement to the mutation spectra being derived from
DNA sequencing efforts. We applied MethylMix indi-
vidually on each cancer site to identify the cancer-
specific heterogeneity in the methylome; in addition, we
created a pancancer methylation map by applying
MethylMix on all 12 cancers sites simultaneously.l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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MethylMix: a beta mixture model to identify differential
and transcriptionally predictive methylation states
To identify key methylation-driven genes, we developed
a model-based method called MethylMix that addresses
all three criteria stated above (Figure S1 in Additional
file 1). First, MethylMix uses a univariate beta mixture
model to identify ‘methylation states’ for each CpG site
(or cluster of correlated CpG sites), which is then associ-
ated with its nearest gene. Each methylation state is de-
fined by a statistically similar methylation pattern across
a large number of patients, removing the need for arbi-
trary thresholds. Second, MethylMix compares the DNA
methylation of cancer with the methylation state in nor-
mal tissue to determine if a specific gene is differentially
methylated in cancer. Since the normal state of DNA
methylation is tissue specific, MethylMix incorporates
the DNA methylation of normal tissue obtained from a
subset of cancer patients in the same tissue to determine
if a specific gene is hyper- or hypomethylated in that
specific tissue type. Next, MethylMix produces a new
metric called the ‘differential methylation value’ or ‘DM-
value’ defined as the difference between the cancer
methylation state and the normal methylation state. Fi-
nally, MethylMix defines the methylation state of a gene
as ‘transcriptionally predictive’ if its gene expression can
sufficiently be predicted by methylation of its CpG sites
using a linear regression model.
MethylMix identifies differential and transcriptionally
predictive genes in 12 cancers
First we applied MethylMix individually on 12 cancer
sites from TCGA: bladder cancer (BLCA), breast cancer
(BRCA), colon cancer (COAD), glioblastoma (GBM),
head and neck squamous carcinoma (HNSC), clear cellTable 1 Overview of the number of samples for each TCGA ca
methylated genes as identified by MethylMix
TCGA cancer code Number of
cancer samples
Number of
normal samples
Nu
hy
BLCA 123 6 443
BRCA 313 27 798
COAD 415 71 526
GBM 402 4 246
HNSC 310 50 728
KIRC 500 355 319
LAML 194 28 470
LUAD 430 47 576
LUSC 358 64 605
OV 584 7 234
READ 162 12 321
UCEC 500 34 618renal carcinoma (KIRC), acute myeloid leukemia
(LAML), lung adeno carcinoma (LUAD), lung squamous
carcinoma (LUSC), serous ovarian cancer (OV), rectal
cancer (READ) and endometrial carcinoma (UCEC), to-
taling 4,291 patients. Using MethylMix we identified
hyper- and hypomethylated genes, and dual genes -
genes with two methylation statuses, hypermethylated in
one subgroup and hypomethylated in another subgroup
of patients - in a particular cancer. This resulted in be-
tween 408 and 1,133 genes called differentially and tran-
scriptionally predictive methylated by MethylMix in
each cancer (Table 1). For all cancers we identified more
hypermethylated genes than hypomethylated genes. For
each cancer we also found a significant number of dual
genes, suggesting a dependence on the genomic context
as these genes can switch from a tumor suppressor role,
through hypermethylation, to an oncogene role via hy-
pomethylation, depending on the context. Particularly
for AML we identified a large number of dual genes.
We compared MethylMix with three previously devel-
oped methods to determine differential methylation:
IMA [9], COHCAP [10] and minfi [11]. Table S1 in
Additional file 2 shows a comparison of the number of
hyper- and hypomethylated genes for all methods. IMA
and COHCAP identify significantly more hyper- and
hypomethylated genes for most cancer sites compared
with MethylMix. Minfi is similar to IMA and COHAP
but does not identify hypomethylated genes. Genes iden-
tified only by IMA, COHCAP or minfi were enriched
with genes that are not transcriptionally predictive
whereas genes uniquely identified by MethylMix were
typically differentially methylated in less than 50% of the
samples (Table S2 in Additional file 2). More specifically,
when focusing on the transcriptionally predictive genes,
MethylMix identifies 94 hyper- and 15 hypomethylatedncer site and the number of hyper-, hypo- and dual
mber of
permethylated genes
Number of
hypomethylated genes
Number of
dual genes
74 23
203 132
102 72
140 22
101 42
251 32
77 164
182 39
133 38
229 66
75 37
238 77
Gevaert et al. Genome Biology  (2015) 16:17 Page 3 of 13genes with a prevalence of less than 15% compared with
between 3 and 5 hypermethylated genes and only 1
hypomethylated gene for IMA, COHCAP and minfi, on
average, across all cancers (Table S2B in Additional file
2). For example, IMA does not identify BRCA1 hyper-
methylation in breast cancer while MethylMix identifies
BRCA1 hypermethylation in 8% of breast cancer
patients.
Next, we investigated for all methods the enrichment
of genes with cancer driver genes identified using inde-
pendent information. More specifically, we identified for
each cancer site genes significantly correlated with can-
cer pathological stage at the gene expression level. For
four cancer sites we were able to identify a sufficient
number of cancer stage driver genes and showed that
genes identified by MethylMix are more enriched with
cancer stage driver genes compared with those identified
by IMA, COHCAP and minfi (Table S3 in Additional
file 2).
Top ranked hyper- and hypomethylated genes
Next, we ranked the MethylMix genes by the prevalence
of their hypo- or hypermethylation state in the 12 can-
cers separately for hyper- and hypomethylation and ex-
cluding dual genes (Tables S4 and S5 in Additional file
2). We identified 266 pancancer hypermethylated genes
and 42 pancancer hypomethylated genes with differential
methylation in at least five cancer sites. Seven genes
are hypermethylated in ten cancer sites: six encoding
zinc finger transcription factors (ZNF135, ZNF354C,
ZNF415, ZNF542, ZNF671, ZSCAN18) and one encod-
ing a transmembrane protein (TMEM25). The top hypo-
methylated gene, MAGEA4, is hypomethylated in nine
cancer sites. We also investigated the gene expression
fold change for the top ranked methylation-driven genes
between the differential methylation state and the nor-
mal state (Tables S6 and S7 in Additional file 2). The top
hypermethylated genes were down-regulated 3.3-fold, on
average, over each of the corresponding 10 cancer sites.
The top hypomethylated gene, MAGEA4, was up-
regulated 121-fold, on average, for each of the nine can-
cer sites it is hypomethylated in.
Hypermethylation suppresses differentiation
We investigated the enrichment of molecular pathways
in the hyper- and hypomethylated genes in all 12 cancer
sites using enrichment analysis. We specifically looked at
the enrichment of stem cell gene sets based on previous
reports describing epigenetic stem cell signatures in can-
cer [12]. We focused on stem cell gene sets that are dif-
ferentially enriched in the hyper- versus hypomethylated
genes and only found gene sets that are exclusively
enriched in hypermethylated genes (Table S8 in
Additional file 2). These genes sets are related tosuppression of genes involved in differentiation, such as
genes repressed by co-binding of POU5F1 (also known
as OCT4), SOX2 and NANOG [13]; genes affected by
knockdown of TCL1A (also known as TCL1) [14]; a
polycomb target module and targets of SMAD1 and
ZNF281 [15], and genes differentially expressed after
RNA interference knockdown of NANOG [16].MethylMix identifies both known and novel methylation
subtypes
We constructed a pipeline to identify methylation-
defined patient subgroups with common hyper- and hy-
pomethylation patterns. We used consensus clustering
to identify robust subgroups of patients based on DM-
values [17]. The best studied methylation subgroups
have been described in colorectal cancer, GBM and
LAML [18]. We identified similar hypermethylated phe-
notypes in these cancers. In COAD, we confirmed the
C-CIMP or C-CIMP-high subtype using DM-values, and
its correlation with MLH1 silencing and BRAF mutation
(Figure 1A) [19]. Next, we confirmed the hypermethy-
lated phenotype in GBM, also known as G-CIMP [20],
and the hypermethylated phenotype in LAML, also
known as L-CIMP characterized by IDH1 or IDH2 mu-
tations [21] (Figure 1B,C; Figures S2, S3 and S4 in
Additional file 1). Additionally, we confirmed a basal
enriched methylation subtype in BRCA described previ-
ously, next to three other methylation subgroups (Figure
S5 in Additional file 1) [22].
We also discovered that the DM-value clustering is su-
perior to other clustering approaches. Clustering with
the beta values instead of the DM-values resulted in
lower intra-cluster and higher inter-cluster consensus
(Table S9 in Additional file 2) and identified significantly
less coherent CIMP subtypes for COAD and LAML
(Table S10 in Additional file 2). Clustering using RPMM,
a methylation specific clustering algorithm [23], did not
result in discovery of the known CIMP groups (Figure
S6 in Additional file 1; Table S11 in Additional file 2).
Next, we compared the DM-value clustering with clus-
tering of the matched gene expression data to investigate
if the DM-value-derived clusters capture unique sub-
groups. This resulted in lower quality gene expression
clusters characterized by lower intra-cluster and higher
inter-cluster consensus compared with clustering DM-
values for the majority of cancer sites (Table S12 in
Additional file 2). Additionally, comparisons of each
gene expression clustering with the corresponding DM-
value clustering using the Jaccard coefficient shows low
correspondence (Table S12 in Additional file 2). Qualita-
tive analysis of the known CIMP groups for COAD,
GBM and LAML show that gene expression clustering
identifies clusters enriched with the COAD and GBM
Figure 1 Consensus clustering [17] and methylation profiles for three cancer sites with known CIMP groups. (A) Colon cancer (COAD);
(B) glioblastoma (GBM); (C) acute myeloid leukemia (LAML). Top panel: visualization of the consensus clustering with blue indicating high
consensus and white indicating low consensus. Bottom panel: methylation profile with red indicating hypermethylation, white indicating normal
methylation and blue indicating hypomethylation. Middle panels: COAD - CIMP-high, CIMP-low subgroups according to [19], MLH1 hypermethylation
and BRAF mutation; GBM - CIMP subgroup; LAML - IDHx mutation in IDH1 or IDH2, mutation in WT1 and AXL1.
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S7 in Additional file 1).
In addition to confirming known methylation sub-
groups, we further identified several subgroups that have
previously not been well studied or reported. We identi-
fied five methylation clusters for KIRC that have a spe-
cific methylation pattern significantly correlated with
tumor stage (P-value <0.001; Figure 2A) and with sur-
vival (P-value <0.001; Figure 2B). Two clusters are
enriched with high stage tumors and have poor survival.
Cluster 5 is correlated with low stage tumors and also
has the fewest non-zero DM-values, reflecting a normal-
like KIRC tumor. The good prognosis cluster, cluster 3,
is characterized by hypermethylation of CYTIP, with
65% of all hypermethylated cases in cluster 3 (Figure 2C)
and virtually all samples in cluster 3 are CYTIP hyper-
methylated (n = 192/204). This observation is consistent
with CYTIP’s role in KIRC protecting cancer cells from
apoptosis signals and based on its previously shown epi-
genetic protective effect [24].
For HNSC we identified five distinct clusters signifi-
cantly correlated with distinct mutational patters for
each cluster (Figure 3A). Interestingly, cluster 2 was sig-
nificantly associated with mutations in NSD1 (P-value
<0.001); more than half of the cluster 2 samples carry a
mutation. Next, cluster 4 is enriched with CASP8 and
NOTCH1 mutations (P-value <0.001 and <0.001, re-
spectively), both of which have been strongly implicated
in HNSC [25]. This group is also characterized by hyper-
methylation of BCL2, with more than 50% of the hyper-methylated cases being in cluster 4 (Figure 3C), and vir-
tually all cases in cluster 4 having BCL2 hypermethylated
(that is, 75 out of 77 cases). Lastly, cluster 5, which does
not have any of the key mutations present in the other
clusters, showed a markedly better survival compared
with the other groups (P-value <0.001) and was enriched
with low stage tumors (P-value <0.001).
For UCEC we identified four methylation clusters that
are correlated with histology and microsatellite instabil-
ity (MSI; Figure 4A). Clusters 1 and 3 are enriched with
endometrioid tumors whereas cluster 3 is a mixture of
endometrioid and serous tumors (P-value <0.001). Clus-
ter 1 is strongly correlated with the TCGA MSI cluster
that has been proposed as a CIMP cluster in endometrial
carcinoma [26]. This cluster is dominated by hyperme-
thylation (Figure S8 in Additional file 1). Although this
CIMP group is associated with MLH1 hypermethylation,
MethylMix identified other hypermethylated genes that
characterize this group, such as hypermethylation of
ELOVL4 and EPM2AIP1, a gene sharing a promoter with
MLH1 (Figure 4B).
Pan-cancer DNA methylation landscape
Next we used MethylMix to define methylation states
across all 12 cancers combined. First, we identified the
methylation states in all normal samples across all 12
cancer sites to select unimodal transcriptionally predict-
ive genes and eliminate heterogeneity in the normal
methylation data (Figure S9 in Additional file 1). This
resulted in 1,780 genes with unimodal methylation in
Figure 2 Clear cell renal carcinoma (KIRC) methylation clustering. (A) Consensus clustering [17] in five subgroups, correlation with
pathologic M stage and binarized pathologic stage (stages 3 and 4 versus stages 1 and 2) and their corresponding methylation profiles with red
indicating hypermethylation, white indicating normal methylation and blue indicating hypomethylation. (B) Overall survival for the five
methylation subgroups. (C) MethylMix model for the CYTIP gene and distribution of CYTIP hypermethylation across the five KIRC subgroups.
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samples using only these 1,780 unimodal genes and
identified the pancancer DM-values. This resulted in
1,028 transcriptionally predictive genes with differential
pancancer methylation states. We used consensus clus-
tering on the corresponding DM-values of these 1,029
genes to identify pancancer clusters (Figure 5). We
found 10 pancancer clusters showing significant tissue-
specific enrichment (Table S13 in Additional file 2), cor-
responding tissue-specific correlations with mutations
(Figure S10 in Additional file 1) and survival (Figure S11
in Additional file 1).
Six pancancer clusters, namely pancancer clusters 1, 4,
5, 7, 9 and 10, are tissue specific and correspond to colo-
rectal, GBM, LAML, KIRC, UCEC and BRCA pancancer
clusters, respectively. The remaining four clusters con-
tain tumors from multiple tissues (Table S13 in
Additional file 2). We used enrichment analysis of over-
expressed genes to assess the commonalities that are
exclusively enriched in each pancancer cluster across
tissues.A striking example is pancancer cluster 2, containing a
mixture of LUAD, LUSC, BLCA, HNSC and BRCA
(Figure 5). BRCA samples in this cluster are almost
exclusively basal breast cancers (27 out of 32 BRCA
cases in pancancer cluster 2). The lung cancer samples
are not enriched in TCGA expression subtypes [27]; ra-
ther, pancancer cluster 2 is exclusively enriched in ex-
pression of collagen genes and the associated syndecan 1
and integrin pathways (Table S14 in Additional file 2),
defining a syndecan-integrin signaling cluster.
Pancancer cluster 3 contains the remaining LUAD
cases and a significant portion of BLCA, LUSC and
UCEC. This cluster has striking enrichment of immune
response genes and the FOXA1 transcriptional network
(Table S14 in Additional file 2), defining a FOXA-
immune response cluster. This cluster also has high ex-
pression of other parts of the integrin signaling pathway
when compared with pancancer cluster 2.
Next, pancancer cluster 6 illustrates that a subset of
UCEC tumors has a similar methylation pattern as the
OV tumors. These UCEC samples are characterized by
Figure 3 Head and neck squamous carcinoma (HNSC) methylation clustering. (A) Consensus clustering [17] in five subgroups, mutation
status for four genes (NSD1, CASP8, NOTCH1 and TP53) and their corresponding methylation profiles with red indicating hypermethylation, white
indicating normal methylation and blue indicating hypomethylation. (B) Overall survival for the five methylation subgroups. (C) MethylMix model
for the BCL2 gene and distribution of BCL2 hypermethylation across the five HNSC subgroups.
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with the UCEC pancancer cluster 9 (P-value <0.001), de-
fining a serous ovarian-endometrial cluster. In addition,
the UCEC tumors in cluster 6 significantly overlap with
the high copy number TCGA subgroup [26] (P-value
<0.001).
Pancancer cluster 8 captures a squamous methylation
pattern based on its composition of most HNSC tumors
and also a subset of LUSC and BLCA tumors. The LUSC
tumors are enriched with the classical TCGA subtype
(P-value <0.001) and the BLCA tumors are enriched for
only papillary tumors and are more likely to be low stage
(P-value 0.003), together they are defining a squamous-
like cluster. We also observed a significant correlation
between mutations in the lincRNA ADAM6 and
pancancer cluster 8 (P-value <0.001; Figure S10 in
Additional file 1). ADAM6 mutations appear across tis-
sue in pancancer cluster 8, including in HNSC, LUSC
and BLCA cases.
Finally, we compared the DM-value pancancer clusters
with previously reported pancancer clusters based on
mutation, copy number data, gene expression data [28]and a meta-clustering analysis combining all of the
above [29]. Comparing the DM-value pancancer clusters
with the mutation and copy number pancancer clusters
demonstrates the unique aspects of the DM-value pan-
cancer clusters, with very few copy number or mutation
pancancer clusters capturing the same phenomenon
(Figures S12 and S13 in Additional file 1). The mutation
pancancer clusters show significant overlap with the
KIRC and OV pancancer clusters (Figure S12 in
Additional file 1). The copy number pancancer clusters
show overlap with the colorectal, GBM and again the
KIRC cluster (Figure S13 in Additional file 1). None of
the pancancer mutation and copy number clusters, how-
ever, identify any of the four cross-tissue pancancer clus-
ters. Similarly, comparison with the gene expression
clustering and the meta-clustering shows that both of
these analyses do not capture the four pancancer clus-
ters that we identified with DM-value clustering (Figures
S14 and S15 in Additional file 1). First, both these clus-
terings do not identify the similarities between serous
endometrial cancer and serous ovarian cancer. Next,
the squamous-like pancancer cluster in both of these
Figure 4 Endometrial cancer (UCEC) methylation clustering. (A) Consensus clustering [17] in four subgroups, corresponding histology (that is,
serous or endometrioid), microsatellite instability (MSI cluster), and methylation profiles with red indicating hypermethylation, white indicating
normal methylation and blue indicating hypomethylation. (B) Hypermethylation of MLH1, ELOVL4 and EPM2AIP1 across the four UCEC subgroups.
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lung squamous carcinoma, and does not distinguish
between the lung squamous carcinoma in the syndecan-
integrin signaling cluster and the pure squamous cluster.
Similarly, both clusterings do not identify the difference
between lung adenocarcinoma in the FOXA-immune
cluster and the syndecan-integrin-squamous like lung
adenocarcinoma.
Discussion
This study represents a large analysis of DNA methyla-
tion in over 4,000 tumors and across 12 cancer sites
from TCGA using a novel computational approach.DNA methylation at CpG sites is an extensively studied
epigenetic mechanism driving oncogenesis. Loss or gain
of CpG site DNA methylation can result in activation of
oncogenes or inactivation of tumor suppressor genes.
Therefore, DNA methylation is increasingly being recog-
nized as a critical mechanism responsible for the transi-
tion from a normal to a malignant cellular phenotype
[30] and a possible driver of therapeutic resistance [31],
and we have shown that differentially methylated genes
are potential cancer driver genes [2,32].
Our results show the existence of pancancer hypo-
and hypermethylated genes. The former are potential
pancancer drug targets whereas the latter have
Figure 5 Pancancer methylation clustering. Left: consensus clustering [17] in 10 subgroups, corresponding cancer sites and their
corresponding methylation profiles with red indicating hypermethylation, white indicating normal methylation and blue indicating
hypomethylation. Right: cancer site distribution for four pancancer clusters with mixed cancer site distributions (pancancer clusters C2, C3, C6
and C8).
Gevaert et al. Genome Biology  (2015) 16:17 Page 8 of 13diagnostic value as potential pancancer biomarkers.
Next, we found distinct methylation-driven subtypes in
each cancer site. We identified between three and five
clusters in each of the 12 cancer sites studied. This in-
cludes both previously studied methylation subtypes,
such as the CIMP subtype [18], but also new subgroups.
Applying MethylMix to the combined pancancer data
set identified 10 methylation subgroups, including four
clusters with significant presence of multiple tissues.
Our findings emphasize the importance of studying
aberrant DNA methylation in cancer and we identified
surprising commonalities across cancers arising from
different tissues.
Our application of MethylMix on each cancer site in-
dividually identified meaningful hypermethylated genes
and also hypomethylated genes, which have not been
studied extensively before. We identified several genes
that are hyper- and hypomethylated in multiple cancers
individually, resulting in 266 pancancer hypermethylated
genes and 42 pancancer hypomethylated genes. One of
the top hypermethylated genes, TMEM25, has been im-
plicated in colorectal cancer [33] and is correlated with
favorable prognosis in breast cancer, confirming a poten-
tial widespread tumor suppressor role for TMEM25
[34]. Similarly, the top hypomethylated gene, MAGEA4,
is hypomethylated across nine cancers in between 18%
and 60% of cases depending on the tissue. MAGEA4 is a
cancer/testis antigen and a target for immunotherapy
and has been identified to promote growth [35].
MAGEA4 is also a therapeutic target in breast cancer
[36] where we observed hypomethylation in 18% of
BRCA cases. Moreover, a family member, MAGEA3, iscurrently the target of a phase three clinical trial for
non-small cell lung cancer [37]. This identifies aberrant
methylation of MAGEA4 as a cause of its widespread
upregulation and as a potential target for immunother-
apy in multiple cancers.
Previous studies on DNA methylation have focused
almost exclusively on hypermethylation leading to the
identification of the CIMP subgroups in at least three
cancer sites, colorectal, LAML and glioma. However,
hypermethylation only offers a partial view of DNA
methylation and our pancancer application of Methyl-
Mix is rooted in an unbiased approach to identify
methylation subtypes. This allowed us to identify not
just the known CIMP subgroups but also novel sub-
groups that are defined by both hyper- and hypomethy-
lation patterns. This is illustrated by the new metric that
we proposed, the DM-value, reflecting differential DNA
methylation with respect to normal DNA methylation
status. We used the DM-value as the basis to define
methylation subtypes in each of the 12 cancer sites. Our
results show that the DM-value is superior to the beta
value for determining subgroups (Tables S9 and S10 in
Additional file 2) and outperformed a dedicated methy-
lation clustering algorithm (Table S11 in Additional file
2). DM-value clustering also resulted in subgroups not
previously described in HNSC, UCEC, and KIRC, with
prognostically significant correlations for KIRC and
HNSC. Moreover, we identified a subtype of HNSC that
is potentially caused by NSD1 mutations. NSD1 is a SET
domain histone methyltransferase that demethylates nu-
cleosomal histone H3 lysine 36. Its mutational pattern
suggests a loss of function creating aberrant histone
Gevaert et al. Genome Biology  (2015) 16:17 Page 9 of 13methylation, also affecting DNA methylation processes
through DNA-histone methylation crosstalk [38], and
thereby potentially defining the NSD1 HNSC subtype.
Finally, we applied MethylMix across all tissues simul-
taneously and identified pancancer clusters. This ‘pan-
cancer map’ illustrates the relationships between the
methylation patterns in different tissues and methylation
patterns common across tissues. Our map revealed six
pancancer clusters that are heavily enriched in one tis-
sue, illustrating that, due to DNA methylation being a
tissue mark, aberrant DNA methylation heavily reflects
the tissue of origin. Besides these homogeneous clusters,
we also identified four mixed pancancer clusters. We
identified two mixed clusters primarily enriched with
lung cancers: a syndecan-integrin signaling cluster and
a FOXA-immune response cluster (that is, pancancer
clusters 2 and 3, Figure 5). The former captures a basal
phenotype enriched in genes related to the integrin sig-
naling pathway whereas the latter is exclusively enriched
in immune response genes. For the remaining two mixed
clusters, we discovered a serous ovarian-endometrial
subgroup, creating opportunities for similar treatment of
these UCEC tumors. This is consistent with the observa-
tion by TCGA that serous uterine tumors have similar
gene expression patterns as serous ovarian cancers [26].
The final cluster we identified is a squamous-like pan-
cancer cluster containing most of the HNSC cases to-
gether with a subset of classical LUSC and papillary
BLCA. Both the LUSC and BLCA samples in this cluster
had a tendency for better prognosis compared with the
remaining samples (data not shown). We also observed
an unexpected similarity between LAML cancers and
KIRC cancers, although clustering in two different pan-
cancer clusters (that is, pancancer clusters 5 and 7), they
have the highest off-diagonal consensus (Figure 4). Com-
parison with previously reported pancancer clusters
based on mutation, copy number data, gene expression
and meta-clustering, combining all of the above, show
the unique aspects of the methylation-based pancancer
map. In addition, none of these other pancancer cluster-
ings identified the mixed tissue pancancer clusters,
such as the serous ovarian-endometrial cluster and the
FOXA-immune response cluster.
By design MethylMix focuses on identifying cis-regula-
tory effects of DNA methylation on gene expression and
does not currently model trans-regulatory effects. Fur-
ther studies are needed to tackle the multiple testing
challenge of identifying trans-regulatory DNA methyla-
tion effects. Additionally, we focused on gene specific
hyper- and hypomethylation as opposed to identifying
regional or genome scale DNA methylation patterns as
shown by other studies [39]. This choice was motivated
based on the properties of the TCGA DNA methylation
platforms that focus primarily on identifying promoterDNA methylation and warrant gene-specific study com-
plementary to previous work.
Conclusions
Our analysis is far from complete but as more tumor
types are completed by TCGA a more comprehensive
picture will emerge identifying more cross-tissue methy-
lation patterns. Identifying commonalities across cancers
originating from different tissues can help to move away
from a paradigm based on treating cancers based on
anatomy to one based on treatment based on common
DNA methylation patterns.
Materials and methods
We developed MethylMix, a novel multi-step model-
based algorithm to determine significant hypo- and
hypermethylated transcriptionally predictive genes in
cancer (Figure S1 in Additional file 1).
The Cancer Genome Atlas pancancer data
We used level three normalized pancancer data from
TCGA for 12 tissues: BLCA, BRCA, COAD, HNSC,
LAML, KIRC, LUAD, LUSC, GBM, READ, UCEC and
OV [40,41]. We used all available DNA methylation and
RNA-Seq gene expression data from TCGA PAN Cancer
Freeze 4.7 available through synapse [42].
Preprocessing DNA methylation data
The DNA methylation data in TCGA was generated
using the Illumina Infinium HumanMethylation 27 k or
450 k BeadChip. DNA methylation was quantified using
beta values ranging from 0 to 1, with values close to 0
indicating low levels of DNA methylation and close to 1
high levels of DNA methylation. We removed CpG sites
with more than 10% missing values in all samples. We
used the 15-K Nearest Neighbor (KNN) algorithm to es-
timate the remaining missing values in the data set [43].
For cancer sites that had both 27 k and 450 k data, the
overlapping probes between both data sets were used.
For all other data sets, all 27 k or all 450 k probes were
used. Due to the size of TCGA, TCGA samples were an-
alyzed in batches and a significant batch effect was ob-
served based on a one-way analysis of variance. We
applied Combat to adjust for these effects [44]. This pro-
cedure was performed for all primary tumor samples
and normal solid tissue. For GBM, four normal samples
were obtained from [20,45].
The 27 k and 450 k DNA methylation platforms have
multiple CpG sites per gene, thereby requiring a method
to collapse the data of multiple CpG sites to assess gene-
specific DNA methylation. Because averaging all CpG
sites can remove signal from the data, we used a dimen-
sionality reduction method to group correlated probes
and reduce redundancy. To accomplish this, we used
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ation with Pearson correlation. This cluster algorithm
groups CpG sites based on a minimum correlation and
keeps them separate when they do not satisfy this mini-
mum correlation threshold. First, the average linkage
hierarchical clustering algorithm was used to cluster all
probes of a single gene into CpG clusters. Then we cut
off the hierarchical tree at a Pearson correlation thresh-
old of 0.4 to define CpG site clusters and single CpG
sites when they do not correlate with other sites, result-
ing in potentially multiple CpG site clusters representing
a single gene.
Preprocessing gene expression data
RNA-seq gene expression data were available for most
primary tumor samples. We log-transformed the RNA-
seq counts and replaced infinities with a low value.
Missing values were estimated similarly as for the DNA
methylation data using 15-KNN [46]. Batch correction
was done using Combat [44].
MethylMix: identifying transcriptionally predictive and
differentially methylated genes in cancer
MethylMix identifies transcriptionally predictive and
differentially methylated genes in cancer via a three-step
algorithm, depicted in Figure 1, and described in detail
below.
Step 1: identifying the methylation state of each CpG site
using univariate beta mixture models
After preprocessing, the methylation data are repre-
sented by ratios bounded between 0 and 1 representing
the proportion of methylated signal versus total signal.
These proportions or beta values are beta-distributed
and we applied beta mixture modeling to identify sub-
populations of patients with similar DNA methylation
levels for each gene using only the cancer methylation
data [47]. Next, for each CpG site, we used a stepwise
approach to determine the minimum number of mixture
components that best fit the patient data. We use the
Bayesian Information Criterion (BIC) for model selec-
tion and to avoid overfitting:
−2  log Lð Þ þ k  log Nð Þ
where k is the number of parameters of the univariate
beta mixture model, L is the likelihood and N is the
number of data points. BIC is more conservative than
the similar Akaike Information Criterion because it pe-
nalizes the free parameters more. This process involves
iteratively adding a new mixture component if the BIC
improves. This procedure is repeated for each CpG site
or CpG cluster and results in a parameterized model of
a mixture of beta distributions. For a CpG site, each betamixture represents a subset of patients for whom a par-
ticular beta distribution of DNA methylation states are
observed.
Step 2: defining hyper- and hypomethylated cancer genes
relative to normal
To determine if a specific CpG cluster is hypo- or hyper-
methylated in cancer, we compare its methylation level
with the DNA methylation levels of normal tissue sam-
ples. We compare the mean of each of the mixture com-
ponents of each CpG site with the average methylation
of its counterpart in the normal samples. We use a
Wilcoxon rank sum test to determine a significant
difference based on a significant Q-value of 0.05 calcu-
lated using P-value multiple testing correction with false
discovery rate (FDR). In addition, we require a minimum
difference of 0.10 based on the platform sensitivity re-
ported in [48].
Step 3: identifying transcriptionally predictive methylation
MethylMix requires that the DNA methylation level
of a gene has a significant effect on its corresponding
gene expression to be considered a methylation-driven
gene. We used linear regression to model the expression
of each gene in terms of its own DNA methylation.
The performance of the model was estimated using the
R-square statistic on the unseen data in each cross-
validation loop. For subsequent enrichment and cluster-
ing analyses we used a P-value threshold of 0.001 and
an R-square of at least 0.10 and required a negative
correlation between methylation and matched gene
expression.
Comparison of MethylMix with IMA, COHCAP and minfi
We compared MethylMix with three previously pub-
lished methods: IMA [9], COHCAP [10] and minfi [11].
IMA is conceptually based on a statistical test compar-
ing the methylation values of a CpG site between cancer
and normal. We used IMA with the default Wilcoxon
rank sum test to determine statistical significance with
the same thresholds as for MethylMix, namely a P-value
threshold of 0.01 and a minimum difference of the beta
value between cancer and normal of 0.1 based on the
platform sensitivity [48].
COHCAP combines several steps of methylation mod-
eling and also includes a differential methylation step.
COHCAP discretizes the methylation data based on
user-specified thresholds and uses a discrete test. We
used COHCAP without the default cutoffs as this
resulted in very few genes being called differentially
methylated for many cancer sites, and set the methyla-
tion and unmethylation cutoffs to 0 and 1, respectively.
We used a delta cutoff of 0.1 to be consistent with
MethylMix.
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analysis of methylation data. This includes a differential
methylation step based on an F-test. We again used a
Q-value threshold of 0.05 and included a methylation
difference filter of 0.1 to be consistent with all
other methods. Minfi does not identify differential
hypomethylation.
We compared IMA, COHCAP and minfi with Methyl-
Mix by investigating their enrichment with cancer driver
genes. We used correlation of gene expression with can-
cer stage to identify potential cancer driver genes using
independent information. We used the spearman correl-
ation test to identify genes significantly correlated with
cancer stage. We corrected for multiple testing using the
FDR [49] and selected only genes with Q-value <0.1.
Next, we investigated the intersection between hyper-
methylated genes and genes negatively correlated with
cancer stage (that is, putative tumor suppressor genes),
and the intersection between hypomethylated genes and
genes positively correlated with cancer stage (that is, pu-
tative oncogenes). We compared the numbers for IMA,
COHCAP, minfi and MethylMix to identify the potential
of each method to find cancer stage driver genes. Next,
we only focused on cancer sites for which at least 200
significant genes could be identified. Three cancer sites
do not have relevant cancer stage information, GBM
(only advanced stage), LAML (different cancer stage
classification) and ovarian cancer (only advanced stage).Identifying patient subgroups based on differential
methylation values
Similar to copy number data analysis, the mixture model
feature of MethylMix allows us to generate a ‘differential’
DNA methylation value by clustering each DNA methy-
lation measurement to its nearest mixture component.
We represent each sample by its differential methylation
value, or DM-value, defined as the difference of the
mean of the mixture component it clusters in and the
mean of normal DNA methylation. This essentially cre-
ates a differentially methylated data set. Next, we clus-
tered the DM-values using consensus clustering for each
cancer and compared with known methylation sub-
groups. This analysis was limited to mixture components
that have significantly different DNA methylation com-
pared with normal and thus focused only on aberrantly
methylated CpG sites or clusters. We compared cluster-
ing of the DM-values with clustering of the beta values
to identify the benefit of using methylation states com-
pared with beta values for identifying patient subgroups.
We used consensus clustering as a clustering algorithm
and also compared with RPMM [23], a dedicated clus-
tering algorithm for DNA methylation data (see the
‘Clustering analysis’ section below).Pancancer MethylMix analysis
To create a pancancer methylation map across all
tissues, we used the following workflow (Figure S9 in
Additional file 1). First, we used MethylMix on the
combined methylation data of all normal tissue samples.
Next, we selected all genes that only have one beta dis-
tribution in the mixture model. These genes are defined
as unimodal genes in the normal DNA methylation
data. Next we intersected this list with genes that are
transcriptionally predictive in the pancancer analysis
based on a significant negative correlation between
DNA methylation and gene expression in the combined
pancancer DNA methylation and gene expression data.
Then we applied MethylMix on all the cancer samples
using the unimodal transcriptionally predictive genes
only. This resulted in a matrix with the pancancer DM-
values for all samples. This matrix was further analyzed
using consensus clustering (see the ‘Clustering analysis’
section below).Clustering analysis
We used consensus clustering [17] to identify robust
clusters defined by DM-values within each tissue and
across all cancers (see the ‘Pancancer MethylMix ana-
lysis’ section above). For the cluster analysis within each
tissue we used the following parameters: maximum nr of
clusters = 10, number of subsamples = 1,000 with 0.8 the
proportion of the subsample and we used the k-means
cluster algorithm with Euclidean distance. For clustering
of the pancancer DM-values we used the same consen-
sus cluster parameters except we investigated up to 20
clusters. Next, we used PAM analysis to identify the cen-
troids for each cluster [50] and SAM analysis to identify
differentially expressed genes for each cluster [51]. For
SAM analysis we used the Wilcoxon rank sum test and
100 permutations. SAM differentially expressed genes
were analyzed with gene set enrichment analysis (see the
‘Gene set enrichment analysis’ section below).
We compared consensus clustering with a dedicated
cluster algorithm for methylation data called RPMM
[23]. RPMM is a model-based recursive-partitioning
clustering algorithm that specifically models the beta
values. We used RPMM on the genes identified
by MethylMix corresponding to both differential and
transcriptionally predictive genes. In addition we also
ran RPMM on the top 25% most varying genes based on
their beta value methylation profiles. Using default
RPMM parameters resulted in an impractically high
number of between 50 and 100 clusters identified for
individual cancer sites. Therefore, we restricted the
maximum level of the hierarchical tree to three, resulting
in a maximum of nine clusters, consistent with our
consensus clustering default parameters.
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To evaluate the gene set enrichment of hyper- and
hypomethylated gene, we used several databases,
namely MSigDB version 3 [52], GeneSetDB version 4
[53], CHEA for CHIP-X gene sets version 2 [54] and
manually curated gene sets related to stem cells and im-
mune gene sets. We used a hypergeometric test to check
for enrichment of gene sets in gene lists. We corrected
for multiple testing using the FDR [49]. We used Fisher’s
method to combine P-values of the pathway enrichment
for all 12 cancers.
We used the gene set enrichment analysis to identify
unique enrichment to characterize the pancancer clus-
ters. For each cluster we used SAM to identify the up-
regulated genes for each cluster and then used the gene
set enrichment procedure to investigate the enrichment
of the gene list databases. Next, we only looked at the
gene sets that are uniquely enriched in each pancancer
cluster with the following cutoffs: P-value <0.0001,
Q-value <0.05, SAM fold change >1.Survival analysis
We used Cox proportional hazards modeling to investi-
gate univariate relationships between DM-values and
survival (survival R package v.2.36-10). Hazard ratios
were used to report the direction of the survival effect
and the Wald test was used to determine significance of
Cox models. We used Kaplan-Meier survival curves to
visualize survival relationships. We used multiple testing
correction with FDR to correct for multiple testing
and calculate Q-values [49]. We focused on genes with
Q-value <15%.Software availability
MethylMix was implemented as an R package [55] and
is available at [56] or through bioconductor at [57].Additional files
Additional file 1: Supplementary figures: compilation of all
supplementary figures visualizing supporting data.
Additional file 2: Supplementary tables: compilation of all
supplementary tables containing supporting data.Abbreviations
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